nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetylsalicylic acid—TP53—urinary bladder cancer	0.396	0.837	CbGaD
Acetylsalicylic acid—PTGS2—urinary bladder cancer	0.0774	0.164	CbGaD
Acetylsalicylic acid—SLC22A7—Fluorouracil—urinary bladder cancer	0.0426	0.163	CbGbCtD
Acetylsalicylic acid—ABCB1—Mitomycin—urinary bladder cancer	0.0327	0.126	CbGbCtD
Acetylsalicylic acid—SLC22A7—Methotrexate—urinary bladder cancer	0.0235	0.0902	CbGbCtD
Acetylsalicylic acid—PTGS2—Cisplatin—urinary bladder cancer	0.0208	0.0798	CbGbCtD
Acetylsalicylic acid—PTGS2—Etoposide—urinary bladder cancer	0.0204	0.0784	CbGbCtD
Acetylsalicylic acid—PTGS1—Etoposide—urinary bladder cancer	0.0172	0.0662	CbGbCtD
Acetylsalicylic acid—ALB—Fluorouracil—urinary bladder cancer	0.0154	0.0592	CbGbCtD
Acetylsalicylic acid—CYP2C8—Fluorouracil—urinary bladder cancer	0.0119	0.0458	CbGbCtD
Acetylsalicylic acid—SLC22A6—Methotrexate—urinary bladder cancer	0.00998	0.0383	CbGbCtD
Acetylsalicylic acid—CYP2C8—Etoposide—urinary bladder cancer	0.00994	0.0382	CbGbCtD
Acetylsalicylic acid—ABCB1—Gemcitabine—urinary bladder cancer	0.00943	0.0362	CbGbCtD
Acetylsalicylic acid—ALB—Methotrexate—urinary bladder cancer	0.0085	0.0327	CbGbCtD
Acetylsalicylic acid—CYP2C9—Fluorouracil—urinary bladder cancer	0.00831	0.0319	CbGbCtD
Acetylsalicylic acid—CYP2C9—Cisplatin—urinary bladder cancer	0.00706	0.0271	CbGbCtD
Acetylsalicylic acid—ABCB1—Cisplatin—urinary bladder cancer	0.00685	0.0263	CbGbCtD
Acetylsalicylic acid—ABCB1—Etoposide—urinary bladder cancer	0.00673	0.0259	CbGbCtD
Acetylsalicylic acid—ABCB1—Doxorubicin—urinary bladder cancer	0.00459	0.0176	CbGbCtD
Acetylsalicylic acid—ABCB1—Methotrexate—urinary bladder cancer	0.00445	0.0171	CbGbCtD
Acetylsalicylic acid—TP53—prostate gland—urinary bladder cancer	0.0022	0.0328	CbGeAlD
Acetylsalicylic acid—NFKBIA—prostate gland—urinary bladder cancer	0.00217	0.0322	CbGeAlD
Acetylsalicylic acid—HSPA5—prostate gland—urinary bladder cancer	0.00212	0.0316	CbGeAlD
Acetylsalicylic acid—NFKBIA—seminal vesicle—urinary bladder cancer	0.00183	0.0273	CbGeAlD
Acetylsalicylic acid—RPS6KA3—prostate gland—urinary bladder cancer	0.00181	0.0269	CbGeAlD
Acetylsalicylic acid—HSPA5—seminal vesicle—urinary bladder cancer	0.00179	0.0267	CbGeAlD
Acetylsalicylic acid—CYP2C19—urine—urinary bladder cancer	0.00175	0.026	CbGeAlD
Acetylsalicylic acid—TP53—epithelium—urinary bladder cancer	0.00162	0.0241	CbGeAlD
Acetylsalicylic acid—NFKBIA—epithelium—urinary bladder cancer	0.00159	0.0237	CbGeAlD
Acetylsalicylic acid—HSPA5—epithelium—urinary bladder cancer	0.00156	0.0232	CbGeAlD
Acetylsalicylic acid—TP53—smooth muscle tissue—urinary bladder cancer	0.00156	0.0232	CbGeAlD
Acetylsalicylic acid—NFKBIA—smooth muscle tissue—urinary bladder cancer	0.00153	0.0228	CbGeAlD
Acetylsalicylic acid—RPS6KA3—seminal vesicle—urinary bladder cancer	0.00153	0.0227	CbGeAlD
Acetylsalicylic acid—HSPA5—smooth muscle tissue—urinary bladder cancer	0.0015	0.0223	CbGeAlD
Acetylsalicylic acid—TP53—renal system—urinary bladder cancer	0.0015	0.0223	CbGeAlD
Acetylsalicylic acid—NFKBIA—renal system—urinary bladder cancer	0.00148	0.022	CbGeAlD
Acetylsalicylic acid—TP53—urethra—urinary bladder cancer	0.00147	0.0219	CbGeAlD
Acetylsalicylic acid—EDNRA—prostate gland—urinary bladder cancer	0.00147	0.0219	CbGeAlD
Acetylsalicylic acid—NFKBIA—urethra—urinary bladder cancer	0.00145	0.0216	CbGeAlD
Acetylsalicylic acid—HSPA5—renal system—urinary bladder cancer	0.00145	0.0215	CbGeAlD
Acetylsalicylic acid—HSPA5—urethra—urinary bladder cancer	0.00142	0.0211	CbGeAlD
Acetylsalicylic acid—CYP2C9—urine—urinary bladder cancer	0.00135	0.0201	CbGeAlD
Acetylsalicylic acid—IKBKB—prostate gland—urinary bladder cancer	0.00133	0.0198	CbGeAlD
Acetylsalicylic acid—EDNRA—seminal vesicle—urinary bladder cancer	0.00124	0.0185	CbGeAlD
Acetylsalicylic acid—RPS6KA3—renal system—urinary bladder cancer	0.00123	0.0183	CbGeAlD
Acetylsalicylic acid—RPS6KA3—urethra—urinary bladder cancer	0.00121	0.018	CbGeAlD
Acetylsalicylic acid—TP53—female reproductive system—urinary bladder cancer	0.0012	0.0179	CbGeAlD
Acetylsalicylic acid—NFKBIA—female reproductive system—urinary bladder cancer	0.00118	0.0176	CbGeAlD
Acetylsalicylic acid—HSPA5—female reproductive system—urinary bladder cancer	0.00116	0.0172	CbGeAlD
Acetylsalicylic acid—TP53—vagina—urinary bladder cancer	0.00109	0.0162	CbGeAlD
Acetylsalicylic acid—NFKBIA—vagina—urinary bladder cancer	0.00107	0.0159	CbGeAlD
Acetylsalicylic acid—HSPA5—vagina—urinary bladder cancer	0.00105	0.0156	CbGeAlD
Acetylsalicylic acid—RPS6KA3—female reproductive system—urinary bladder cancer	0.000986	0.0147	CbGeAlD
Acetylsalicylic acid—EDNRA—urethra—urinary bladder cancer	0.000983	0.0146	CbGeAlD
Acetylsalicylic acid—IKBKB—smooth muscle tissue—urinary bladder cancer	0.000944	0.0141	CbGeAlD
Acetylsalicylic acid—IKBKB—urethra—urinary bladder cancer	0.000893	0.0133	CbGeAlD
Acetylsalicylic acid—RPS6KA3—vagina—urinary bladder cancer	0.000892	0.0133	CbGeAlD
Acetylsalicylic acid—SLC22A7—renal system—urinary bladder cancer	0.000881	0.0131	CbGeAlD
Acetylsalicylic acid—IKBKB—female reproductive system—urinary bladder cancer	0.000728	0.0108	CbGeAlD
Acetylsalicylic acid—EDNRA—vagina—urinary bladder cancer	0.000725	0.0108	CbGeAlD
Acetylsalicylic acid—TP53—lymph node—urinary bladder cancer	0.000703	0.0105	CbGeAlD
Acetylsalicylic acid—NFKBIA—lymph node—urinary bladder cancer	0.000691	0.0103	CbGeAlD
Acetylsalicylic acid—HSPA5—lymph node—urinary bladder cancer	0.000677	0.0101	CbGeAlD
Acetylsalicylic acid—IKBKB—vagina—urinary bladder cancer	0.000658	0.0098	CbGeAlD
Acetylsalicylic acid—RPS6KA3—lymph node—urinary bladder cancer	0.000577	0.00858	CbGeAlD
Acetylsalicylic acid—Salicylate-sodium—PTGS2—urinary bladder cancer	0.000552	0.338	CrCbGaD
Acetylsalicylic acid—NFKBIA—Epirubicin—Valrubicin—urinary bladder cancer	0.000515	0.132	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Doxorubicin—Valrubicin—urinary bladder cancer	0.000515	0.132	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Daunorubicin—Valrubicin—urinary bladder cancer	0.000515	0.132	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Idarubicin—Valrubicin—urinary bladder cancer	0.000515	0.132	CbGdCrCtD
Acetylsalicylic acid—EDNRA—lymph node—urinary bladder cancer	0.000469	0.00698	CbGeAlD
Acetylsalicylic acid—TP53—Podofilox—Etoposide—urinary bladder cancer	0.000453	0.116	CbGdCrCtD
Acetylsalicylic acid—PTGS1—prostate gland—urinary bladder cancer	0.000444	0.0066	CbGeAlD
Acetylsalicylic acid—IKBKB—lymph node—urinary bladder cancer	0.000426	0.00634	CbGeAlD
Acetylsalicylic acid—PTGS2—prostate gland—urinary bladder cancer	0.000424	0.00631	CbGeAlD
Acetylsalicylic acid—PTGS1—seminal vesicle—urinary bladder cancer	0.000375	0.00558	CbGeAlD
Acetylsalicylic acid—CYP2C8—renal system—urinary bladder cancer	0.000373	0.00555	CbGeAlD
Acetylsalicylic acid—PTGS2—seminal vesicle—urinary bladder cancer	0.000359	0.00534	CbGeAlD
Acetylsalicylic acid—NFKBIA—Podofilox—Etoposide—urinary bladder cancer	0.000344	0.0883	CbGdCrCtD
Acetylsalicylic acid—PTGS1—epithelium—urinary bladder cancer	0.000326	0.00485	CbGeAlD
Acetylsalicylic acid—Salsalate—PTGS2—urinary bladder cancer	0.000322	0.197	CrCbGaD
Acetylsalicylic acid—Meclofenamic acid—PTGS2—urinary bladder cancer	0.000317	0.194	CrCbGaD
Acetylsalicylic acid—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000314	0.00467	CbGeAlD
Acetylsalicylic acid—PTGS2—epithelium—urinary bladder cancer	0.000312	0.00464	CbGeAlD
Acetylsalicylic acid—CYP2C19—vagina—urinary bladder cancer	0.000309	0.00461	CbGeAlD
Acetylsalicylic acid—PTGS1—renal system—urinary bladder cancer	0.000302	0.0045	CbGeAlD
Acetylsalicylic acid—PTGS2—smooth muscle tissue—urinary bladder cancer	0.0003	0.00447	CbGeAlD
Acetylsalicylic acid—CYP2C8—female reproductive system—urinary bladder cancer	0.000299	0.00444	CbGeAlD
Acetylsalicylic acid—PTGS2—renal system—urinary bladder cancer	0.000289	0.0043	CbGeAlD
Acetylsalicylic acid—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.000288	0.00469	CcSEcCtD
Acetylsalicylic acid—PTGS2—urethra—urinary bladder cancer	0.000284	0.00423	CbGeAlD
Acetylsalicylic acid—Haematemesis—Doxorubicin—urinary bladder cancer	0.000278	0.00452	CcSEcCtD
Acetylsalicylic acid—Influenza—Gemcitabine—urinary bladder cancer	0.000274	0.00445	CcSEcCtD
Acetylsalicylic acid—CYP2C8—vagina—urinary bladder cancer	0.00027	0.00402	CbGeAlD
Acetylsalicylic acid—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000269	0.00437	CcSEcCtD
Acetylsalicylic acid—CYP2C9—female reproductive system—urinary bladder cancer	0.000265	0.00395	CbGeAlD
Acetylsalicylic acid—ABCB1—prostate gland—urinary bladder cancer	0.000262	0.0039	CbGeAlD
Acetylsalicylic acid—Haemoglobin—Thiotepa—urinary bladder cancer	0.000262	0.00426	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Thiotepa—urinary bladder cancer	0.00026	0.00424	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Mitomycin—urinary bladder cancer	0.000252	0.0041	CcSEcCtD
Acetylsalicylic acid—ALB—lymph node—urinary bladder cancer	0.000249	0.0037	CbGeAlD
Acetylsalicylic acid—Mefenamic acid—PTGS2—urinary bladder cancer	0.000247	0.151	CrCbGaD
Acetylsalicylic acid—Dizziness—Mitomycin—urinary bladder cancer	0.000243	0.00396	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Thiotepa—urinary bladder cancer	0.000243	0.00395	CcSEcCtD
Acetylsalicylic acid—PTGS1—female reproductive system—urinary bladder cancer	0.000242	0.0036	CbGeAlD
Acetylsalicylic acid—Ulcer—Methotrexate—urinary bladder cancer	0.000236	0.00384	CcSEcCtD
Acetylsalicylic acid—Sweating—Gemcitabine—urinary bladder cancer	0.000234	0.00381	CcSEcCtD
Acetylsalicylic acid—Vomiting—Mitomycin—urinary bladder cancer	0.000234	0.00381	CcSEcCtD
Acetylsalicylic acid—Rash—Mitomycin—urinary bladder cancer	0.000232	0.00377	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Mitomycin—urinary bladder cancer	0.000232	0.00377	CcSEcCtD
Acetylsalicylic acid—PTGS2—female reproductive system—urinary bladder cancer	0.000231	0.00344	CbGeAlD
Acetylsalicylic acid—Respiratory failure—Methotrexate—urinary bladder cancer	0.000227	0.0037	CcSEcCtD
Acetylsalicylic acid—ABCB1—seminal vesicle—urinary bladder cancer	0.000222	0.0033	CbGeAlD
Acetylsalicylic acid—Ulcer—Epirubicin—urinary bladder cancer	0.000221	0.00359	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00022	0.00358	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000219	0.00356	CcSEcCtD
Acetylsalicylic acid—PTGS1—vagina—urinary bladder cancer	0.000219	0.00326	CbGeAlD
Acetylsalicylic acid—Nausea—Mitomycin—urinary bladder cancer	0.000218	0.00356	CcSEcCtD
Acetylsalicylic acid—Melaena—Methotrexate—urinary bladder cancer	0.000218	0.00355	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000216	0.00352	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000215	0.0035	CcSEcCtD
Acetylsalicylic acid—Anaemia—Thiotepa—urinary bladder cancer	0.000209	0.00341	CcSEcCtD
Acetylsalicylic acid—PTGS2—vagina—urinary bladder cancer	0.000209	0.00312	CbGeAlD
Acetylsalicylic acid—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.000209	0.0034	CcSEcCtD
Acetylsalicylic acid—Agitation—Thiotepa—urinary bladder cancer	0.000208	0.00339	CcSEcCtD
Acetylsalicylic acid—Ulcer—Doxorubicin—urinary bladder cancer	0.000204	0.00332	CcSEcCtD
Acetylsalicylic acid—Melaena—Epirubicin—urinary bladder cancer	0.000204	0.00332	CcSEcCtD
Acetylsalicylic acid—Coma—Methotrexate—urinary bladder cancer	0.000204	0.00332	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Thiotepa—urinary bladder cancer	0.000203	0.0033	CcSEcCtD
Acetylsalicylic acid—Salicylic acid—PTGS2—urinary bladder cancer	0.000198	0.121	CrCbGaD
Acetylsalicylic acid—Convulsion—Thiotepa—urinary bladder cancer	0.000196	0.0032	CcSEcCtD
Acetylsalicylic acid—Hypertension—Thiotepa—urinary bladder cancer	0.000196	0.00318	CcSEcCtD
Acetylsalicylic acid—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.000193	0.00314	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Thiotepa—urinary bladder cancer	0.000193	0.00314	CcSEcCtD
Acetylsalicylic acid—ABCB1—epithelium—urinary bladder cancer	0.000193	0.00287	CbGeAlD
Acetylsalicylic acid—Coma—Epirubicin—urinary bladder cancer	0.000191	0.0031	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Cisplatin—urinary bladder cancer	0.00019	0.0031	CcSEcCtD
Acetylsalicylic acid—Flushing—Cisplatin—urinary bladder cancer	0.000189	0.00308	CcSEcCtD
Acetylsalicylic acid—Melaena—Doxorubicin—urinary bladder cancer	0.000189	0.00307	CcSEcCtD
Acetylsalicylic acid—Confusional state—Thiotepa—urinary bladder cancer	0.000186	0.00303	CcSEcCtD
Acetylsalicylic acid—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000186	0.00303	CcSEcCtD
Acetylsalicylic acid—Polyuria—Methotrexate—urinary bladder cancer	0.000184	0.003	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000181	0.00295	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Thiotepa—urinary bladder cancer	0.000181	0.00294	CcSEcCtD
Acetylsalicylic acid—NFKBIA—Idarubicin—Epirubicin—urinary bladder cancer	0.000179	0.046	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Doxorubicin—Epirubicin—urinary bladder cancer	0.000179	0.046	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Daunorubicin—Epirubicin—urinary bladder cancer	0.000179	0.046	CbGdCrCtD
Acetylsalicylic acid—ABCB1—renal system—urinary bladder cancer	0.000179	0.00266	CbGeAlD
Acetylsalicylic acid—Coma—Doxorubicin—urinary bladder cancer	0.000176	0.00287	CcSEcCtD
Acetylsalicylic acid—Anaemia—Gemcitabine—urinary bladder cancer	0.000176	0.00287	CcSEcCtD
Acetylsalicylic acid—ABCB1—urethra—urinary bladder cancer	0.000176	0.00261	CbGeAlD
Acetylsalicylic acid—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000174	0.00283	CcSEcCtD
Acetylsalicylic acid—Flushing—Etoposide—urinary bladder cancer	0.000174	0.00282	CcSEcCtD
Acetylsalicylic acid—Anaemia—Fluorouracil—urinary bladder cancer	0.000173	0.00282	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Gemcitabine—urinary bladder cancer	0.000171	0.00278	CcSEcCtD
Acetylsalicylic acid—Vascular purpura—Epirubicin—urinary bladder cancer	0.000169	0.00276	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Fluorouracil—urinary bladder cancer	0.000168	0.00273	CcSEcCtD
Acetylsalicylic acid—NFKBIA—Idarubicin—Doxorubicin—urinary bladder cancer	0.000166	0.0426	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000166	0.0426	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Epirubicin—Doxorubicin—urinary bladder cancer	0.000166	0.0426	CbGdCrCtD
Acetylsalicylic acid—Hypertension—Gemcitabine—urinary bladder cancer	0.000165	0.00268	CcSEcCtD
Acetylsalicylic acid—Somnolence—Thiotepa—urinary bladder cancer	0.000164	0.00268	CcSEcCtD
Acetylsalicylic acid—Anaemia—Cisplatin—urinary bladder cancer	0.000164	0.00267	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Thiotepa—urinary bladder cancer	0.000163	0.00265	CcSEcCtD
Acetylsalicylic acid—Convulsion—Fluorouracil—urinary bladder cancer	0.000162	0.00264	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Gemcitabine—urinary bladder cancer	0.000162	0.00264	CcSEcCtD
Acetylsalicylic acid—Chest pain—Gemcitabine—urinary bladder cancer	0.000162	0.00264	CcSEcCtD
Acetylsalicylic acid—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000161	0.00262	CcSEcCtD
Acetylsalicylic acid—Chest pain—Fluorouracil—urinary bladder cancer	0.00016	0.0026	CcSEcCtD
Acetylsalicylic acid—Renal impairment—Epirubicin—urinary bladder cancer	0.000159	0.00259	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Cisplatin—urinary bladder cancer	0.000159	0.00259	CcSEcCtD
Acetylsalicylic acid—Purpura—Epirubicin—urinary bladder cancer	0.000157	0.00256	CcSEcCtD
Acetylsalicylic acid—Vascular purpura—Doxorubicin—urinary bladder cancer	0.000157	0.00255	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000156	0.00253	CcSEcCtD
Acetylsalicylic acid—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000155	0.00253	CcSEcCtD
Acetylsalicylic acid—Confusional state—Fluorouracil—urinary bladder cancer	0.000154	0.00251	CcSEcCtD
Acetylsalicylic acid—Convulsion—Cisplatin—urinary bladder cancer	0.000154	0.00251	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000153	0.00249	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000152	0.00248	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000152	0.00248	CcSEcCtD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000152	0.00247	CcSEcCtD
Acetylsalicylic acid—Anaemia—Etoposide—urinary bladder cancer	0.00015	0.00245	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00015	0.00245	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00015	0.00244	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Fluorouracil—urinary bladder cancer	0.000149	0.00243	CcSEcCtD
Acetylsalicylic acid—Renal impairment—Doxorubicin—urinary bladder cancer	0.000147	0.0024	CcSEcCtD
Acetylsalicylic acid—Urticaria—Thiotepa—urinary bladder cancer	0.000147	0.00239	CcSEcCtD
Acetylsalicylic acid—Vertigo—Etoposide—urinary bladder cancer	0.000146	0.00238	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Etoposide—urinary bladder cancer	0.000146	0.00237	CcSEcCtD
Acetylsalicylic acid—Purpura—Doxorubicin—urinary bladder cancer	0.000145	0.00237	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000145	0.00236	CcSEcCtD
Acetylsalicylic acid—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000144	0.00234	CcSEcCtD
Acetylsalicylic acid—ABCB1—female reproductive system—urinary bladder cancer	0.000143	0.00213	CbGeAlD
Acetylsalicylic acid—Loss of consciousness—Etoposide—urinary bladder cancer	0.000143	0.00233	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000142	0.00231	CcSEcCtD
Acetylsalicylic acid—PTGS1—lymph node—urinary bladder cancer	0.000142	0.00211	CbGeAlD
Acetylsalicylic acid—Tachycardia—Cisplatin—urinary bladder cancer	0.000142	0.0023	CcSEcCtD
Acetylsalicylic acid—Convulsion—Etoposide—urinary bladder cancer	0.000141	0.0023	CcSEcCtD
Acetylsalicylic acid—Hypertension—Etoposide—urinary bladder cancer	0.000141	0.00229	CcSEcCtD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.00014	0.00228	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00014	0.00228	CcSEcCtD
Acetylsalicylic acid—Asthma—Methotrexate—urinary bladder cancer	0.00014	0.00228	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000139	0.00226	CcSEcCtD
Acetylsalicylic acid—Chest pain—Etoposide—urinary bladder cancer	0.000139	0.00226	CcSEcCtD
Acetylsalicylic acid—Somnolence—Gemcitabine—urinary bladder cancer	0.000138	0.00225	CcSEcCtD
Acetylsalicylic acid—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000138	0.00224	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000136	0.00222	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000136	0.00222	CcSEcCtD
Acetylsalicylic acid—Somnolence—Fluorouracil—urinary bladder cancer	0.000136	0.00221	CcSEcCtD
Acetylsalicylic acid—PTGS2—lymph node—urinary bladder cancer	0.000135	0.00202	CbGeAlD
Acetylsalicylic acid—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000135	0.00219	CcSEcCtD
Acetylsalicylic acid—Confusional state—Etoposide—urinary bladder cancer	0.000134	0.00218	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000133	0.00216	CcSEcCtD
Acetylsalicylic acid—Asthma—Epirubicin—urinary bladder cancer	0.000131	0.00213	CcSEcCtD
Acetylsalicylic acid—Influenza—Epirubicin—urinary bladder cancer	0.000131	0.00213	CcSEcCtD
Acetylsalicylic acid—Pruritus—Thiotepa—urinary bladder cancer	0.000131	0.00213	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00013	0.00212	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Etoposide—urinary bladder cancer	0.00013	0.00211	CcSEcCtD
Acetylsalicylic acid—ABCB1—vagina—urinary bladder cancer	0.000129	0.00193	CbGeAlD
Acetylsalicylic acid—Dyspnoea—Cisplatin—urinary bladder cancer	0.000129	0.0021	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000128	0.00209	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000128	0.00209	CcSEcCtD
Acetylsalicylic acid—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000128	0.00208	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Thiotepa—urinary bladder cancer	0.000127	0.00206	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000126	0.00205	CcSEcCtD
Acetylsalicylic acid—Drowsiness—Methotrexate—urinary bladder cancer	0.000125	0.00203	CcSEcCtD
Acetylsalicylic acid—Dizziness—Thiotepa—urinary bladder cancer	0.000122	0.00199	CcSEcCtD
Acetylsalicylic acid—Urticaria—Fluorouracil—urinary bladder cancer	0.000122	0.00198	CcSEcCtD
Acetylsalicylic acid—Influenza—Doxorubicin—urinary bladder cancer	0.000121	0.00197	CcSEcCtD
Acetylsalicylic acid—Asthma—Doxorubicin—urinary bladder cancer	0.000121	0.00197	CcSEcCtD
Acetylsalicylic acid—Sweating—Methotrexate—urinary bladder cancer	0.00012	0.00195	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00012	0.00194	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Etoposide—urinary bladder cancer	0.000118	0.00193	CcSEcCtD
Acetylsalicylic acid—Somnolence—Etoposide—urinary bladder cancer	0.000118	0.00192	CcSEcCtD
Acetylsalicylic acid—Vomiting—Thiotepa—urinary bladder cancer	0.000118	0.00191	CcSEcCtD
Acetylsalicylic acid—Drowsiness—Epirubicin—urinary bladder cancer	0.000117	0.0019	CcSEcCtD
Acetylsalicylic acid—Rash—Thiotepa—urinary bladder cancer	0.000117	0.0019	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Thiotepa—urinary bladder cancer	0.000117	0.0019	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000113	0.00183	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Methotrexate—urinary bladder cancer	0.000113	0.00183	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Methotrexate—urinary bladder cancer	0.000112	0.00182	CcSEcCtD
Acetylsalicylic acid—Sweating—Epirubicin—urinary bladder cancer	0.000112	0.00182	CcSEcCtD
Acetylsalicylic acid—Pruritus—Gemcitabine—urinary bladder cancer	0.00011	0.00179	CcSEcCtD
Acetylsalicylic acid—Nausea—Thiotepa—urinary bladder cancer	0.00011	0.00179	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Etoposide—urinary bladder cancer	0.000109	0.00178	CcSEcCtD
Acetylsalicylic acid—Pruritus—Fluorouracil—urinary bladder cancer	0.000108	0.00176	CcSEcCtD
Acetylsalicylic acid—Drowsiness—Doxorubicin—urinary bladder cancer	0.000108	0.00176	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000107	0.00174	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000106	0.00173	CcSEcCtD
Acetylsalicylic acid—Urticaria—Etoposide—urinary bladder cancer	0.000106	0.00172	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Epirubicin—urinary bladder cancer	0.000105	0.00171	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Epirubicin—urinary bladder cancer	0.000105	0.00171	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000105	0.0017	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Methotrexate—urinary bladder cancer	0.000104	0.0017	CcSEcCtD
Acetylsalicylic acid—Sweating—Doxorubicin—urinary bladder cancer	0.000104	0.00169	CcSEcCtD
Acetylsalicylic acid—Dizziness—Fluorouracil—urinary bladder cancer	0.000101	0.00165	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Cisplatin—urinary bladder cancer	9.92e-05	0.00161	CcSEcCtD
Acetylsalicylic acid—Vomiting—Gemcitabine—urinary bladder cancer	9.89e-05	0.00161	CcSEcCtD
Acetylsalicylic acid—Rash—Gemcitabine—urinary bladder cancer	9.81e-05	0.0016	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Gemcitabine—urinary bladder cancer	9.8e-05	0.00159	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Etoposide—urinary bladder cancer	9.79e-05	0.00159	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Epirubicin—urinary bladder cancer	9.77e-05	0.00159	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Doxorubicin—urinary bladder cancer	9.75e-05	0.00159	CcSEcCtD
Acetylsalicylic acid—Flushing—Epirubicin—urinary bladder cancer	9.73e-05	0.00158	CcSEcCtD
Acetylsalicylic acid—Vomiting—Fluorouracil—urinary bladder cancer	9.73e-05	0.00158	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Doxorubicin—urinary bladder cancer	9.7e-05	0.00158	CcSEcCtD
Acetylsalicylic acid—Rash—Fluorouracil—urinary bladder cancer	9.65e-05	0.00157	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Fluorouracil—urinary bladder cancer	9.64e-05	0.00157	CcSEcCtD
Acetylsalicylic acid—Pruritus—Etoposide—urinary bladder cancer	9.4e-05	0.00153	CcSEcCtD
Acetylsalicylic acid—Nausea—Gemcitabine—urinary bladder cancer	9.24e-05	0.0015	CcSEcCtD
Acetylsalicylic acid—Vomiting—Cisplatin—urinary bladder cancer	9.22e-05	0.0015	CcSEcCtD
Acetylsalicylic acid—Rash—Cisplatin—urinary bladder cancer	9.14e-05	0.00149	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Cisplatin—urinary bladder cancer	9.13e-05	0.00149	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Etoposide—urinary bladder cancer	9.09e-05	0.00148	CcSEcCtD
Acetylsalicylic acid—Nausea—Fluorouracil—urinary bladder cancer	9.09e-05	0.00148	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Doxorubicin—urinary bladder cancer	9.04e-05	0.00147	CcSEcCtD
Acetylsalicylic acid—Anaemia—Methotrexate—urinary bladder cancer	9.01e-05	0.00147	CcSEcCtD
Acetylsalicylic acid—Flushing—Doxorubicin—urinary bladder cancer	9e-05	0.00146	CcSEcCtD
Acetylsalicylic acid—Dizziness—Etoposide—urinary bladder cancer	8.79e-05	0.00143	CcSEcCtD
Acetylsalicylic acid—Vertigo—Methotrexate—urinary bladder cancer	8.76e-05	0.00143	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Methotrexate—urinary bladder cancer	8.73e-05	0.00142	CcSEcCtD
Acetylsalicylic acid—Nausea—Cisplatin—urinary bladder cancer	8.61e-05	0.0014	CcSEcCtD
Acetylsalicylic acid—Convulsion—Methotrexate—urinary bladder cancer	8.45e-05	0.00137	CcSEcCtD
Acetylsalicylic acid—Vomiting—Etoposide—urinary bladder cancer	8.45e-05	0.00137	CcSEcCtD
Acetylsalicylic acid—Anaemia—Epirubicin—urinary bladder cancer	8.43e-05	0.00137	CcSEcCtD
Acetylsalicylic acid—Agitation—Epirubicin—urinary bladder cancer	8.39e-05	0.00136	CcSEcCtD
Acetylsalicylic acid—Rash—Etoposide—urinary bladder cancer	8.38e-05	0.00136	CcSEcCtD
Acetylsalicylic acid—ABCB1—lymph node—urinary bladder cancer	8.37e-05	0.00125	CbGeAlD
Acetylsalicylic acid—Dermatitis—Etoposide—urinary bladder cancer	8.37e-05	0.00136	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Methotrexate—urinary bladder cancer	8.3e-05	0.00135	CcSEcCtD
Acetylsalicylic acid—Chest pain—Methotrexate—urinary bladder cancer	8.3e-05	0.00135	CcSEcCtD
Acetylsalicylic acid—Vertigo—Epirubicin—urinary bladder cancer	8.2e-05	0.00133	CcSEcCtD
Acetylsalicylic acid—Syncope—Epirubicin—urinary bladder cancer	8.18e-05	0.00133	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Epirubicin—urinary bladder cancer	8.17e-05	0.00133	CcSEcCtD
Acetylsalicylic acid—Confusional state—Methotrexate—urinary bladder cancer	8.02e-05	0.00131	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Epirubicin—urinary bladder cancer	8.02e-05	0.00131	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.96e-05	0.0013	CcSEcCtD
Acetylsalicylic acid—Convulsion—Epirubicin—urinary bladder cancer	7.91e-05	0.00129	CcSEcCtD
Acetylsalicylic acid—Nausea—Etoposide—urinary bladder cancer	7.89e-05	0.00128	CcSEcCtD
Acetylsalicylic acid—Hypertension—Epirubicin—urinary bladder cancer	7.88e-05	0.00128	CcSEcCtD
Acetylsalicylic acid—Anaemia—Doxorubicin—urinary bladder cancer	7.8e-05	0.00127	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.79e-05	0.00127	CcSEcCtD
Acetylsalicylic acid—Chest pain—Epirubicin—urinary bladder cancer	7.77e-05	0.00126	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Epirubicin—urinary bladder cancer	7.77e-05	0.00126	CcSEcCtD
Acetylsalicylic acid—Agitation—Doxorubicin—urinary bladder cancer	7.76e-05	0.00126	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.69e-05	0.00125	CcSEcCtD
Acetylsalicylic acid—Vertigo—Doxorubicin—urinary bladder cancer	7.59e-05	0.00123	CcSEcCtD
Acetylsalicylic acid—Syncope—Doxorubicin—urinary bladder cancer	7.57e-05	0.00123	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Doxorubicin—urinary bladder cancer	7.56e-05	0.00123	CcSEcCtD
Acetylsalicylic acid—Confusional state—Epirubicin—urinary bladder cancer	7.51e-05	0.00122	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.45e-05	0.00121	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.42e-05	0.00121	CcSEcCtD
Acetylsalicylic acid—Shock—Epirubicin—urinary bladder cancer	7.33e-05	0.00119	CcSEcCtD
Acetylsalicylic acid—Convulsion—Doxorubicin—urinary bladder cancer	7.32e-05	0.00119	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.29e-05	0.00119	CcSEcCtD
Acetylsalicylic acid—Hypertension—Doxorubicin—urinary bladder cancer	7.29e-05	0.00119	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Epirubicin—urinary bladder cancer	7.27e-05	0.00118	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.2e-05	0.00117	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Doxorubicin—urinary bladder cancer	7.19e-05	0.00117	CcSEcCtD
Acetylsalicylic acid—Chest pain—Doxorubicin—urinary bladder cancer	7.19e-05	0.00117	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Methotrexate—urinary bladder cancer	7.09e-05	0.00115	CcSEcCtD
Acetylsalicylic acid—Somnolence—Methotrexate—urinary bladder cancer	7.07e-05	0.00115	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Methotrexate—urinary bladder cancer	7e-05	0.00114	CcSEcCtD
Acetylsalicylic acid—Confusional state—Doxorubicin—urinary bladder cancer	6.95e-05	0.00113	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.89e-05	0.00112	CcSEcCtD
Acetylsalicylic acid—Shock—Doxorubicin—urinary bladder cancer	6.78e-05	0.0011	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.75e-05	0.0011	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Doxorubicin—urinary bladder cancer	6.73e-05	0.00109	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.66e-05	0.00108	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Epirubicin—urinary bladder cancer	6.64e-05	0.00108	CcSEcCtD
Acetylsalicylic acid—Somnolence—Epirubicin—urinary bladder cancer	6.62e-05	0.00108	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Methotrexate—urinary bladder cancer	6.56e-05	0.00107	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Epirubicin—urinary bladder cancer	6.56e-05	0.00107	CcSEcCtD
Acetylsalicylic acid—Urticaria—Methotrexate—urinary bladder cancer	6.32e-05	0.00103	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Doxorubicin—urinary bladder cancer	6.14e-05	0.001	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Epirubicin—urinary bladder cancer	6.14e-05	0.000999	CcSEcCtD
Acetylsalicylic acid—Somnolence—Doxorubicin—urinary bladder cancer	6.13e-05	0.000997	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Doxorubicin—urinary bladder cancer	6.07e-05	0.000987	CcSEcCtD
Acetylsalicylic acid—Urticaria—Epirubicin—urinary bladder cancer	5.92e-05	0.000963	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Methotrexate—urinary bladder cancer	5.86e-05	0.000954	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.68e-05	0.000924	CcSEcCtD
Acetylsalicylic acid—Pruritus—Methotrexate—urinary bladder cancer	5.63e-05	0.000916	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Epirubicin—urinary bladder cancer	5.49e-05	0.000893	CcSEcCtD
Acetylsalicylic acid—Urticaria—Doxorubicin—urinary bladder cancer	5.47e-05	0.000891	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Methotrexate—urinary bladder cancer	5.44e-05	0.000886	CcSEcCtD
Acetylsalicylic acid—Pruritus—Epirubicin—urinary bladder cancer	5.27e-05	0.000857	CcSEcCtD
Acetylsalicylic acid—Dizziness—Methotrexate—urinary bladder cancer	5.26e-05	0.000856	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Epirubicin—urinary bladder cancer	5.1e-05	0.000829	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.08e-05	0.000826	CcSEcCtD
Acetylsalicylic acid—Vomiting—Methotrexate—urinary bladder cancer	5.06e-05	0.000823	CcSEcCtD
Acetylsalicylic acid—Rash—Methotrexate—urinary bladder cancer	5.02e-05	0.000817	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Methotrexate—urinary bladder cancer	5.01e-05	0.000816	CcSEcCtD
Acetylsalicylic acid—Dizziness—Epirubicin—urinary bladder cancer	4.92e-05	0.000801	CcSEcCtD
Acetylsalicylic acid—Pruritus—Doxorubicin—urinary bladder cancer	4.88e-05	0.000793	CcSEcCtD
Acetylsalicylic acid—Vomiting—Epirubicin—urinary bladder cancer	4.73e-05	0.000771	CcSEcCtD
Acetylsalicylic acid—Nausea—Methotrexate—urinary bladder cancer	4.73e-05	0.000769	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Doxorubicin—urinary bladder cancer	4.71e-05	0.000767	CcSEcCtD
Acetylsalicylic acid—Rash—Epirubicin—urinary bladder cancer	4.7e-05	0.000764	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Epirubicin—urinary bladder cancer	4.69e-05	0.000763	CcSEcCtD
Acetylsalicylic acid—Dizziness—Doxorubicin—urinary bladder cancer	4.56e-05	0.000742	CcSEcCtD
Acetylsalicylic acid—Nausea—Epirubicin—urinary bladder cancer	4.42e-05	0.00072	CcSEcCtD
Acetylsalicylic acid—Vomiting—Doxorubicin—urinary bladder cancer	4.38e-05	0.000713	CcSEcCtD
Acetylsalicylic acid—Rash—Doxorubicin—urinary bladder cancer	4.34e-05	0.000707	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Doxorubicin—urinary bladder cancer	4.34e-05	0.000706	CcSEcCtD
Acetylsalicylic acid—Nausea—Doxorubicin—urinary bladder cancer	4.09e-05	0.000666	CcSEcCtD
Acetylsalicylic acid—CYP2C8—Metabolism—RRM2—urinary bladder cancer	5.56e-06	4.21e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—CDKN1A—urinary bladder cancer	5.55e-06	4.2e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—PTEN—urinary bladder cancer	5.54e-06	4.19e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—RRM2—urinary bladder cancer	5.53e-06	4.18e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—MMP9—urinary bladder cancer	5.51e-06	4.16e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CXCL8—urinary bladder cancer	5.51e-06	4.16e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CXCL8—urinary bladder cancer	5.51e-06	4.16e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—CDKN1A—urinary bladder cancer	5.49e-06	4.15e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—PTEN—urinary bladder cancer	5.47e-06	4.14e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling by GPCR—HRAS—urinary bladder cancer	5.47e-06	4.14e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling by GPCR—HRAS—urinary bladder cancer	5.47e-06	4.14e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.44e-06	4.11e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—CREBBP—urinary bladder cancer	5.37e-06	4.06e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—GSTP1—urinary bladder cancer	5.36e-06	4.05e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CREBBP—urinary bladder cancer	5.33e-06	4.03e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—EGFR—urinary bladder cancer	5.31e-06	4.02e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—KRAS—urinary bladder cancer	5.31e-06	4.02e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—IGF1—urinary bladder cancer	5.31e-06	4.01e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CDH1—urinary bladder cancer	5.29e-06	4e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—EP300—urinary bladder cancer	5.28e-06	3.99e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—IL2—urinary bladder cancer	5.26e-06	3.98e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—IL2—urinary bladder cancer	5.26e-06	3.98e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.25e-06	3.97e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—EP300—urinary bladder cancer	5.22e-06	3.95e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.19e-06	3.92e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	5.15e-06	3.9e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—ENO2—urinary bladder cancer	5.15e-06	3.9e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—SRC—urinary bladder cancer	5.14e-06	3.88e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CCND1—urinary bladder cancer	5.13e-06	3.88e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CCND1—urinary bladder cancer	5.13e-06	3.88e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—HPGDS—urinary bladder cancer	5.12e-06	3.87e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—ENO2—urinary bladder cancer	5.12e-06	3.87e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.12e-06	3.87e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—NQO1—urinary bladder cancer	5.1e-06	3.86e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—EGFR—urinary bladder cancer	5.1e-06	3.86e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.09e-06	3.85e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—SRC—urinary bladder cancer	5.08e-06	3.84e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—KRAS—urinary bladder cancer	5.02e-06	3.8e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—NCOR1—urinary bladder cancer	5.01e-06	3.79e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5e-06	3.78e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—HRAS—urinary bladder cancer	5e-06	3.78e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	5e-06	3.78e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—TYMS—urinary bladder cancer	4.99e-06	3.77e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—MMP9—urinary bladder cancer	4.98e-06	3.76e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—MMP9—urinary bladder cancer	4.98e-06	3.76e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GSTT1—urinary bladder cancer	4.97e-06	3.76e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—RRM2—urinary bladder cancer	4.97e-06	3.75e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—CDKN1A—urinary bladder cancer	4.96e-06	3.75e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—CDKN1A—urinary bladder cancer	4.96e-06	3.75e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—PTEN—urinary bladder cancer	4.95e-06	3.74e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—PTEN—urinary bladder cancer	4.95e-06	3.74e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—NCOR1—urinary bladder cancer	4.93e-06	3.73e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—GSTM1—urinary bladder cancer	4.93e-06	3.73e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.92e-06	3.72e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.89e-06	3.7e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—RHOA—urinary bladder cancer	4.86e-06	3.68e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—RRM2—urinary bladder cancer	4.85e-06	3.66e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—KRAS—urinary bladder cancer	4.82e-06	3.64e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—EP300—urinary bladder cancer	4.72e-06	3.57e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—EP300—urinary bladder cancer	4.72e-06	3.57e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—TP53—urinary bladder cancer	4.72e-06	3.57e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—GPX1—urinary bladder cancer	4.72e-06	3.57e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—NCOR1—urinary bladder cancer	4.67e-06	3.53e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.65e-06	3.52e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—ERCC2—urinary bladder cancer	4.63e-06	3.5e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—MYC—urinary bladder cancer	4.6e-06	3.48e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.6e-06	3.48e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.6e-06	3.48e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—SRC—urinary bladder cancer	4.59e-06	3.47e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—SRC—urinary bladder cancer	4.59e-06	3.47e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.57e-06	3.46e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—MYC—urinary bladder cancer	4.55e-06	3.44e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.53e-06	3.42e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—HRAS—urinary bladder cancer	4.51e-06	3.41e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—EGFR—urinary bladder cancer	4.5e-06	3.4e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—ENO2—urinary bladder cancer	4.49e-06	3.39e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—HPGDS—urinary bladder cancer	4.49e-06	3.39e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—ERBB2—urinary bladder cancer	4.47e-06	3.38e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.46e-06	3.37e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—EGFR—urinary bladder cancer	4.45e-06	3.36e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TERT—urinary bladder cancer	4.41e-06	3.34e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.39e-06	3.32e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—ERCC2—urinary bladder cancer	4.39e-06	3.32e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—MTHFR—urinary bladder cancer	4.36e-06	3.29e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GSTT1—urinary bladder cancer	4.35e-06	3.29e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.32e-06	3.27e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—HRAS—urinary bladder cancer	4.27e-06	3.23e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—GSTP1—urinary bladder cancer	4.26e-06	3.22e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—KRAS—urinary bladder cancer	4.25e-06	3.22e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—KRAS—urinary bladder cancer	4.2e-06	3.18e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.19e-06	3.17e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.19e-06	3.17e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.17e-06	3.15e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—NQO1—urinary bladder cancer	4.15e-06	3.14e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—NQO1—urinary bladder cancer	4.13e-06	3.12e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—MTHFR—urinary bladder cancer	4.13e-06	3.12e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.12e-06	3.11e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—TERT—urinary bladder cancer	4.12e-06	3.11e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—MYC—urinary bladder cancer	4.11e-06	3.11e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—MYC—urinary bladder cancer	4.11e-06	3.11e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—HRAS—urinary bladder cancer	4.1e-06	3.1e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—IL2—urinary bladder cancer	4.08e-06	3.08e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.08e-06	3.08e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.07e-06	3.08e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—FGFR3—urinary bladder cancer	4.05e-06	3.06e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—IL2—urinary bladder cancer	4.05e-06	3.06e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.03e-06	3.05e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—EGFR—urinary bladder cancer	4.02e-06	3.04e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—EGFR—urinary bladder cancer	4.02e-06	3.04e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.01e-06	3.03e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4e-06	3.03e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—TYMS—urinary bladder cancer	3.96e-06	2.99e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—ESR1—urinary bladder cancer	3.93e-06	2.97e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—GSTM1—urinary bladder cancer	3.91e-06	2.96e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—NCOR1—urinary bladder cancer	3.91e-06	2.96e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CDKN1A—urinary bladder cancer	3.82e-06	2.89e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—PTEN—urinary bladder cancer	3.81e-06	2.88e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—KRAS—urinary bladder cancer	3.8e-06	2.87e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—KRAS—urinary bladder cancer	3.8e-06	2.87e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—TP53—urinary bladder cancer	3.78e-06	2.86e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—FGFR3—urinary bladder cancer	3.78e-06	2.86e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—GPX1—urinary bladder cancer	3.75e-06	2.83e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.71e-06	2.8e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—ERCC2—urinary bladder cancer	3.68e-06	2.78e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—EP300—urinary bladder cancer	3.66e-06	2.77e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—EP300—urinary bladder cancer	3.63e-06	2.75e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—NQO1—urinary bladder cancer	3.62e-06	2.74e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—HRAS—urinary bladder cancer	3.61e-06	2.73e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.6e-06	2.72e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—HRAS—urinary bladder cancer	3.57e-06	2.7e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—SRC—urinary bladder cancer	3.56e-06	2.69e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PPARG—urinary bladder cancer	3.53e-06	2.67e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—SRC—urinary bladder cancer	3.53e-06	2.67e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.51e-06	2.66e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.49e-06	2.64e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	3.46e-06	2.62e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—MTHFR—urinary bladder cancer	3.46e-06	2.61e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CREBBP—urinary bladder cancer	3.45e-06	2.61e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GSTP1—urinary bladder cancer	3.44e-06	2.6e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—IGF1—urinary bladder cancer	3.4e-06	2.57e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—CREBBP—urinary bladder cancer	3.39e-06	2.57e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.38e-06	2.56e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—TP53—urinary bladder cancer	3.38e-06	2.55e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—TP53—urinary bladder cancer	3.38e-06	2.55e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.35e-06	2.53e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.33e-06	2.52e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.28e-06	2.48e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—HRAS—urinary bladder cancer	3.23e-06	2.44e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—HRAS—urinary bladder cancer	3.23e-06	2.44e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.22e-06	2.43e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CREBBP—urinary bladder cancer	3.22e-06	2.43e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—TYMS—urinary bladder cancer	3.2e-06	2.42e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.18e-06	2.41e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.18e-06	2.41e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—NCOR1—urinary bladder cancer	3.16e-06	2.39e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GSTM1—urinary bladder cancer	3.16e-06	2.39e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.14e-06	2.37e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—RHOA—urinary bladder cancer	3.12e-06	2.36e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—EGFR—urinary bladder cancer	3.1e-06	2.34e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.09e-06	2.34e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.05e-06	2.3e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GPX1—urinary bladder cancer	3.03e-06	2.29e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.02e-06	2.28e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.99e-06	2.26e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.99e-06	2.26e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—ERCC2—urinary bladder cancer	2.98e-06	2.25e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—KRAS—urinary bladder cancer	2.95e-06	2.23e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—KRAS—urinary bladder cancer	2.92e-06	2.21e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—RHOA—urinary bladder cancer	2.91e-06	2.2e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—ERBB2—urinary bladder cancer	2.89e-06	2.18e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.87e-06	2.17e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.86e-06	2.16e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.84e-06	2.15e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.84e-06	2.15e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.82e-06	2.13e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.81e-06	2.13e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.81e-06	2.12e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PPARG—urinary bladder cancer	2.8e-06	2.12e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—MTHFR—urinary bladder cancer	2.8e-06	2.11e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PTGS2—urinary bladder cancer	2.78e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.77e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.77e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CXCL8—urinary bladder cancer	2.74e-06	2.07e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.73e-06	2.06e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.72e-06	2.06e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—CREBBP—urinary bladder cancer	2.69e-06	2.04e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—ERBB2—urinary bladder cancer	2.69e-06	2.04e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.67e-06	2.02e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.66e-06	2.01e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.62e-06	1.98e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—TP53—urinary bladder cancer	2.62e-06	1.98e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—IL2—urinary bladder cancer	2.62e-06	1.98e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.61e-06	1.97e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.59e-06	1.96e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.59e-06	1.96e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CCND1—urinary bladder cancer	2.55e-06	1.93e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.51e-06	1.9e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—HRAS—urinary bladder cancer	2.5e-06	1.89e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—HRAS—urinary bladder cancer	2.49e-06	1.88e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.48e-06	1.88e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MMP9—urinary bladder cancer	2.48e-06	1.87e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CDKN1A—urinary bladder cancer	2.47e-06	1.87e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—PTEN—urinary bladder cancer	2.46e-06	1.86e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—MTHFR—urinary bladder cancer	2.45e-06	1.85e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.44e-06	1.84e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PTEN—urinary bladder cancer	2.42e-06	1.83e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—EP300—urinary bladder cancer	2.35e-06	1.78e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—EP300—urinary bladder cancer	2.31e-06	1.75e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CDKN1A—urinary bladder cancer	2.3e-06	1.74e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—PTEN—urinary bladder cancer	2.3e-06	1.74e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.29e-06	1.73e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—SRC—urinary bladder cancer	2.28e-06	1.73e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.28e-06	1.72e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PPARG—urinary bladder cancer	2.27e-06	1.72e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.19e-06	1.66e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—EP300—urinary bladder cancer	2.19e-06	1.66e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—CREBBP—urinary bladder cancer	2.18e-06	1.65e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—SRC—urinary bladder cancer	2.13e-06	1.61e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MYC—urinary bladder cancer	2.05e-06	1.55e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.04e-06	1.54e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—EGFR—urinary bladder cancer	2e-06	1.51e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.99e-06	1.5e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.96e-06	1.48e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PTEN—urinary bladder cancer	1.92e-06	1.45e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.91e-06	1.44e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—MYC—urinary bladder cancer	1.91e-06	1.44e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—KRAS—urinary bladder cancer	1.89e-06	1.43e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—EGFR—urinary bladder cancer	1.87e-06	1.41e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.86e-06	1.4e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—EP300—urinary bladder cancer	1.83e-06	1.39e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.79e-06	1.36e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PTGS2—urinary bladder cancer	1.78e-06	1.35e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.78e-06	1.35e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—KRAS—urinary bladder cancer	1.76e-06	1.33e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TP53—urinary bladder cancer	1.68e-06	1.27e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—HRAS—urinary bladder cancer	1.61e-06	1.21e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.6e-06	1.21e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.56e-06	1.18e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.56e-06	1.18e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PTEN—urinary bladder cancer	1.56e-06	1.18e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—HRAS—urinary bladder cancer	1.5e-06	1.13e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.49e-06	1.13e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—EP300—urinary bladder cancer	1.48e-06	1.12e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.46e-06	1.1e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.4e-06	1.06e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.36e-06	1.03e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.33e-06	1.01e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—EP300—urinary bladder cancer	1.3e-06	9.83e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.27e-06	9.63e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.21e-06	9.18e-06	CbGpPWpGaD
